Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081088 | 0.77 | PIK3CG (0.60) | RAB9ANPC1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL7428151 | 0.77 | CSF1R (0.50) | RAB9ANPC1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL716362 | 0.74 | PIK3CG (0.62) | RAB9ANPC1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL10084975 | 0.74 | PIK3CD (0.56) | RAB9ANPC1MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL17801714 | 0.73 | NPC1 (0.66) | RAB9ANPC1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL10080999 | 0.73 | PIK3CG (0.64) | RAB9ANPC1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL14568609 | 0.72 | BRAF (0.46) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL717159 | 0.72 | RAB9A (0.51) | RAB9ANPC1MAPTCYP1A2CYP3A4 | |
| SCHEMBL7475860 | 0.72 | RAB9A (0.48) | RAB9ANPC1MAPTSMN1; SMN2NFKB1 | |
| SCHEMBL1303607 | 0.72 | MEN1 (0.60) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | RAB9A 1134/4885NPC1 1406/4885MAPT 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.